Ampersand Capital Partners
VC Fund
Wellesley, United States
Ampersand Capital Partners is a VC fund in Wellesley focused on Biotechnology and Health Care. Ampersand is a middle market private equity firm that focuses on healthcare and industrial sectors.
- Total investments:
- 73
- Last investment:
- Lead investor:
- 48%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Ampersand Capital Partners invests in
Stages Ampersand Capital Partners invests in
Countries Ampersand Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Blair Patteson
|
|||
David Parker
|
|||
|
David Q. Anderson
|
|||
|
Eric B. Lev
|
|||
|
Marina Pellόn-Consunji
|
|||
| See all 18 contacts → | |||
Investment Focus
Industry
- Biotechnology 33 (45%)
- Health Care 20 (27%)
- Manufacturing 16 (22%)
- Pharmaceutical 14 (19%)
- Medical 11 (15%)
Stage
- Private Equity 26 (36%)
- Funding Round 16 (22%)
- Series A 7 (10%)
- Series B 7 (10%)
- Series C 3 (4%)
Country
- United States 46 (63%)
- Germany 3 (4%)
- Australia 2 (3%)
- The Netherlands 2 (3%)
- Spain 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Blair Patteson
Partner
|
Partner | Total investments: 2 | Find email | |
|
David Parker
General Partner
|
General Partner | Total investments: 2 | Find email | |
|
David Q. Anderson
General Partner
|
General Partner | Total investments: 3 | Find email | |
|
Eric B. Lev
Partner
|
Partner | Total investments: 2 | Find email | |
|
Marina Pellόn-Consunji
Partner
|
Partner | Total investments: 1 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lexington Medical, Inc.
|
We are a Boston-based medical device company that manufactures minimally invasive surgical stapling solutions. With the highest standards in design engineering and smart manufacturing, our specialized team is committed to delivering disruptive innovation to health care providers and their patients. | $37.8M / Private Equity / Apr 17, 2025 | |
VIVEbiotech
|
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors. | Private Equity / Dec 04, 2024 | |
Julius Clinical
|
Julius Clinical specializes in distinct therapeutic areas that offer a full-service proposal or separate functional service. | Private Equity / Nov 28, 2023 | |
ProtaGene
|
ProtaGene is an analytic service provider across the biopharmaceutical, cell, and gene therapy development spaces. They provide complete protein and gene analytic capabilities and packages for biologic therapeutics as well as cell and gene therapy platforms. They offer product testing and analytical packages for product lifecycle management. | Private Equity / Nov 20, 2023 | |
Genezen
|
Genezen offers contract process development, GMP viral vector production, transduced cell manufacturing, and testing services. | $18.5M / Venture - Series Unknown / Nov 02, 2023 | |
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $20M / Series A / Jun 27, 2023 | |
NanoImaging Services
|
NIS launched in 2007 to provide imaging services to the pharmaceutical, biotechnology and nanotechnology communities. They have since built a client-focused organization with a reputation for expertise, reliability and collaboration. NIS is committed to expanding their service capacity through microscope acquisition, workflow automation,recruitment and training of top talent, and the development of new service offerings. Their state-of-the-art facilities include a range of electron microscopes, sample preparation equipment and computational infrastructure to support structural biology, nanoparticle characterization and chemistry workflows. With recent acquisitions, NIS has become the largest and most comprehensive provider of TEM, cryoEM and microED services to the industrial life science market. | Private Equity / Jun 12, 2023 | |
Sterling Medical Devices
|
Sterling Medical Devices, a fully staffed U.S. based medical device engineering firm. | Private Equity / Jun 23, 2022 | |
AnaBios
|
AnaBios specializes in enabling human-focused drug discovery. As a CRO, AnaBios provides products and services for every stage of drug discovery. Through proprietary technology based on the use of human donor organs and tissues, it studies ex vivo human responses to drugs and further investigate the molecular and functional basis of relevant humanphysiology. Its research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease, and neurodegeneration. In partnership with Fortune 500 pharmaceutical companies, contract research organizations, and universities, the company's mission is to develop therapeutic advancements to help patients live longer, healthier, and more productive lives. | $6.5M / Series C / Jun 07, 2022 | |
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Series A / Jun 02, 2022 | |
| See all 73 investments → | |||
Co-Investors
Charles River Laboratories International
2 deals together
Cisco
2 deals together
Corning
2 deals together
Dynamk Capital
2 deals together
New England Partners
2 deals together
Nexus Medical Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ampersand Capital Partners invest in?
Ampersand Capital Partners invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Private Equity and Funding Round stage. Most of the 73 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ampersand Capital Partners?
Public channels for Ampersand Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ampersand Capital Partners?
The team at Ampersand Capital Partners includes David Blair Patteson (Partner), David Parker (General Partner) and David Q. Anderson (General Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
